Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

5.78
-0.0200-0.34%
Post-market: 5.790.0100+0.17%18:43 EDT
Volume:1.07M
Turnover:6.20M
Market Cap:802.94M
PE:-1.44
High:5.95
Open:5.76
Low:5.71
Close:5.80
52wk High:14.45
52wk Low:4.16
Shares:138.92M
Float Shares:94.55M
Volume Ratio:1.10
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0061
EPS(LYR):-3.8310
ROE:-46.22%
ROA:-24.73%
PB:0.85
PE(LYR):-1.51

Loading ...

Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Oct 15

SVF Endurance (Cayman) Ltd. Reports Disposal of Common Shares of Vir Biotechnology Inc

Reuters
·
Oct 15

BRIEF-Vir Biotechnology Announces First Patient Dosed In Part 3 Of Phase 1 Trial

Reuters
·
Oct 10

Vir Biotechnology doses first patient in Phase 1 part 3 trial of VIR-5500

TIPRANKS
·
Oct 10

Vir Biotechnology announces first patient dosed in Phase 1 trial of dual masked T cell engager VIR 5500 for metastatic prostate cancer

Reuters
·
Oct 10

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of Psma-Targeting Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Combination With Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

THOMSON REUTERS
·
Oct 10

Trump Excludes Generics From Big Pharma Tariff Plan

Dow Jones
·
Oct 09

SVF Endurance (Cayman) Ltd Reports Disposal of Common Shares of Vir Biotechnology Inc

Reuters
·
Oct 08

Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025

Reuters
·
Oct 07

Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares

Reuters
·
Oct 02

Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 16

Director Vicki L. Sato Reports Disposal of Common Shares of Vir Biotechnology Inc

Reuters
·
Sep 04

Vir Biotechnology Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Sep 03

Vir Biotechnology Shares Rise After Upgrade From BofA Securities

MT Newswires Live
·
Aug 28

Vir Biotechnology Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Aug 28

Vir Biotechnology Inc : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $14 From $12

THOMSON REUTERS
·
Aug 27

BofA Securities Upgrades Vir Biotechnology to Buy From Neutral, Price Target is $14

MT Newswires Live
·
Aug 27

Vir Biotechnology Inc. CEO to Participate in Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Aug 26

Stock Track | Vir Biotechnology Plummets 5.71% as Q2 Revenue Misses Estimates, Falling 61% Year-over-Year

Stock Track
·
Aug 07

Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss

MT Newswires Live
·
Aug 07